Lactobacillus acidophilus/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases gamma-glutamyl transferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“After 14 days, UDCA+ L. acid group showed significantly lower AST (p < 0.05), ALT (p < 0.05), ALP, GGT (p < 0.05), and TBIL (p < 0.05) compared to UDCA, while no differences were found at the beginning of the trial (Supplemental Table 3).”
Quoted verbatim from Lactobacillus acidophilus ameliorates cholestatic liver injury through inhibiting bile acid synthesis and promoting bile acid excretion.. - Study
- RCT
- Duration
- 14 days
- Dose
- 1 g fixed-dose tablet before each meal, three times a day, for 14 days, added to UDCA
- Population
- Adults with cholestatic liver disease; both arms received ursodeoxycholic acid 250 mg twice daily as background, the control arm UDCA alone; small single-centre trial
Lactobacillus acidophilus ameliorates cholestatic liver injury through inhibiting bile acid synthesis and promoting bile acid excretion.2024PMID:39205654Permalink
Keep reading
- Everything the graph holds on Lactobacillus acidophilus
- Every compound studied against Gamma-glutamyl transferase
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45SWV7XPW111SJDJ6K4AQ7Z